The Skin-Bone Axis in Psoriasis: An Emerging Osteoimmunological Perspective
- 1Department of Dermatology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan
Abstract
Psoriasis is a chronic inflammatory skin disease accompanied by systemic comorbidities such as metabolic syndrome and cardiovascular disease. Bone homeostasis is tightly regulated by immune cells through the receptor activator of nuclear factor-κB ligand (RANKL)–RANK–osteoprotegerin (OPG) axis and inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin (IL)-17. Although bone destruction has been extensively characterized in psoriatic arthritis (PsA), whether the skeleton is affected in psoriasis without clinically apparent arthritis remains unsettled: population-based data suggest a modest, inconsistently replicated excess of fractures, yet pooled analyses show no corresponding reduction in areal bone mineral density. This review integrates evidence from osteoimmunology, the bone marrow immune niche, microbiome research, and clinical studies to propose the skin–bone axis as a conceptual framework linking chronic cutaneous inflammation to systemic skeletal remodeling beyond joint involvement. Because the strength of the supporting evidence varies widely across these domains, we grade each component of the proposed axis explicitly as established, extrapolated, or hypothetical, identifying bone marrow niche remodeling, trained immunity, and microbiome-mediated skeletal regulation as hypothesis-generating rather than demonstrated, and we appraise the confounding introduced by lifestyle, comorbidity, and cumulative corticosteroid exposure. We conclude by defining the knowledge gaps and study designs required to determine whether bone health should be incorporated into psoriasis management.
Related
- A metabolic perspective on eIF1A and eIF3B inhibition as a potential therapeutic strategy in psoriasis
- The gut microbiota-bone marrow axis: an emerging role in chemotherapy-induced myelosuppression
- ERK5 Signaling and Ferroptosis in Bone Homeostasis: Emerging Connections and Therapeutic Perspectives
- Emerging regulatory role of lncRNA MALAT1 in bone homeostasis: from the β–catenin–OPG/Jagged1 signalling axis to a broader regulatory network
- Psoriasis and Bullous Pemphigoid: An Updated Review of Clinical Association, Targeted Therapy Exposures and Therapeutic Implications
BibTeX
@article{saitosasaki2026skinbone,
title = {{The Skin-Bone Axis in Psoriasis: An Emerging Osteoimmunological Perspective}},
author = {Natsuko Saito-Sasaki and Yu Sawada},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208066},
url = {https://www.mdpi.com/2077-0383/15/20/8066},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Skin-Bone Axis in Psoriasis: An Emerging Osteoimmunological Perspective
AU - Natsuko Saito-Sasaki
AU - Yu Sawada
PY - 2026
DA - 2026/10/17
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208066
UR - https://www.mdpi.com/2077-0383/15/20/8066
AB - Psoriasis is a chronic inflammatory skin disease accompanied by systemic comorbidities such as metabolic syndrome and cardiovascular disease. Bone homeostasis is tightly regulated by immune cells through the receptor activator of nuclear factor-κB ligand (RANKL)–RANK–osteoprotegerin (OPG) axis and inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin (IL)-17. Although bone destruction has been extensively characterized in psoriatic arthritis (PsA), whether the skeleton is affected in psoriasis without clinically apparent arthritis remains unsettled: population-based data suggest a modest, inconsistently replicated excess of fractures, yet pooled analyses show no corresponding reduction in areal bone mineral density. This review integrates evidence from osteoimmunology, the bone marrow immune niche, microbiome research, and clinical studies to propose the skin–bone axis as a conceptual framework linking chronic cutaneous inflammation to systemic skeletal remodeling beyond joint involvement. Because the strength of the supporting evidence varies widely across these domains, we grade each component of the proposed axis explicitly as established, extrapolated, or hypothetical, identifying bone marrow niche remodeling, trained immunity, and microbiome-mediated skeletal regulation as hypothesis-generating rather than demonstrated, and we appraise the confounding introduced by lifestyle, comorbidity, and cumulative corticosteroid exposure. We conclude by defining the knowledge gaps and study designs required to determine whether bone health should be incorporated into psoriasis management.
SN - 2077-0383
ER -